239 related articles for article (PubMed ID: 19707583)
1. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells.
Dao T; Korontsvit T; Zakhaleva V; Haro K; Packin J; Scheinberg DA
PLoS One; 2009 Aug; 4(8):e6730. PubMed ID: 19707583
[TBL] [Abstract][Full Text] [Related]
2. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH
Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723
[TBL] [Abstract][Full Text] [Related]
3. HLA class I binding 9mer peptides from influenza A virus induce CD4 T cell responses.
Wang M; Larsen MV; Nielsen M; Harndahl M; Justesen S; Dziegiel MH; Buus S; Tang ST; Lund O; Claesson MH
PLoS One; 2010 May; 5(5):e10533. PubMed ID: 20479886
[TBL] [Abstract][Full Text] [Related]
4. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
[TBL] [Abstract][Full Text] [Related]
5. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
7. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
8. Human Th1 cell lines recognize the Mycobacterium tuberculosis ESAT-6 antigen and its peptides in association with frequently expressed HLA class II molecules.
Mustafa AS; Shaban FA; Al-Attiyah R; Abal AT; El-Shamy AM; Andersen P; Oftung F
Scand J Immunol; 2003 Feb; 57(2):125-34. PubMed ID: 12588658
[TBL] [Abstract][Full Text] [Related]
9. Overlapping epitopes that are recognized by CD8+ HLA class I-restricted and CD4+ class II-restricted cytotoxic T lymphocytes are contained within an influenza nucleoprotein peptide.
Carreno BM; Turner RV; Biddison WE; Coligan JE
J Immunol; 1992 Feb; 148(3):894-9. PubMed ID: 1370522
[TBL] [Abstract][Full Text] [Related]
10. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
[TBL] [Abstract][Full Text] [Related]
11. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
12. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.
Consogno G; Manici S; Facchinetti V; Bachi A; Hammer J; Conti-Fine BM; Rugarli C; Traversari C; Protti MP
Blood; 2003 Feb; 101(3):1038-44. PubMed ID: 12393675
[TBL] [Abstract][Full Text] [Related]
13. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
14. Identification of vaccine candidate peptides in the NcSRS2 surface protein of Neospora caninum by using CD4+ cytotoxic T lymphocytes and gamma interferon-secreting T lymphocytes of infected holstein cattle.
Staska LM; Davies CJ; Brown WC; McGuire TC; Suarez CE; Park JY; Mathison BA; Abbott JR; Baszler TV
Infect Immun; 2005 Mar; 73(3):1321-9. PubMed ID: 15731029
[TBL] [Abstract][Full Text] [Related]
15. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
[TBL] [Abstract][Full Text] [Related]
16. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
18. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
19. Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.
Karyampudi L; Krco CJ; Kalli KR; Erskine CL; Hartmann LC; Goodman K; Ingle JN; Maurer MJ; Nassar A; Yu C; Disis ML; Wettstein PJ; Fikes JD; Beebe M; Ishioka G; Knutson KL
Cancer Immunol Immunother; 2010 Jan; 59(1):161-71. PubMed ID: 19621224
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy.
Kondo E; Maecker B; Weihrauch MR; Wickenhauser C; Zeng W; Nadler LM; Schultze JL; von Bergwelt-Baildon MS
Clin Cancer Res; 2008 Oct; 14(20):6574-9. PubMed ID: 18927298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]